TISIDB

Summary
Symbol	PTPRQ
Name	protein tyrosine phosphatase, receptor type, Q
Aliases	DFNB84; deafness, autosomal recessive 84; DFNB84A; PTPGMC1; R-PTP-Q; phosphotidylinositol phosphatase PTPRQ; ......
Chromosomal Location	12q21.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane Single-pass type I membrane protein
Domain	PF00041 Fibronectin type III domain PF00102 Protein-tyrosine phosphatase
Function	Phosphatidylinositol phosphatase required for auditory function. May act by regulating the level of phosphatidylinositol 4,5-bisphosphate (PIP2) level in the basal region of hair bundles. Can dephosphorylate a broad range of phosphatidylinositol phosphates, including phosphatidylinositol 3,4,5-trisphosphate and most phosphatidylinositol monophosphates and diphosphates. Phosphate can be hydrolyzed from the D3 and D5 positions in the inositol ring. Has low tyrosine-protein phosphatase activity; however, the relevance of such activity in vivo is unclear. Plays an important role in adipogenesis of mesenchymal stem cells (MSCs). Regulates the phosphorylation state of AKT1 by suppressing the phosphatidylinositol 3,4,5-trisphosphate (PIP3) level in MSCs and preadipocyte cells.

> Gene Ontology [ TOP ]
Biological Process	GO:0006470 protein dephosphorylation GO:0006644 phospholipid metabolic process GO:0006650 glycerophospholipid metabolic process GO:0007423 sensory organ development GO:0016311 dephosphorylation GO:0030258 lipid modification GO:0035335 peptidyl-tyrosine dephosphorylation GO:0042471 ear morphogenesis GO:0042472 inner ear morphogenesis GO:0043583 ear development GO:0045444 fat cell differentiation GO:0045598 regulation of fat cell differentiation GO:0046486 glycerolipid metabolic process GO:0046488 phosphatidylinositol metabolic process GO:0046839 phospholipid dephosphorylation GO:0046856 phosphatidylinositol dephosphorylation GO:0048562 embryonic organ morphogenesis GO:0048568 embryonic organ development GO:0048839 inner ear development GO:0090596 sensory organ morphogenesis
Molecular Function	GO:0004721 phosphoprotein phosphatase activity GO:0004725 protein tyrosine phosphatase activity GO:0016791 phosphatase activity GO:0042578 phosphoric ester hydrolase activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	PTPRQ
Name	protein tyrosine phosphatase, receptor type, Q
Aliases	DFNB84; deafness, autosomal recessive 84; DFNB84A; PTPGMC1; R-PTP-Q; phosphotidylinositol phosphatase PTPRQ; ......
Chromosomal Location	12q21.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between PTPRQ and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	PTPRQ
Name	protein tyrosine phosphatase, receptor type, Q
Aliases	DFNB84; deafness, autosomal recessive 84; DFNB84A; PTPGMC1; R-PTP-Q; phosphotidylinositol phosphatase PTPRQ; ......
Chromosomal Location	12q21.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of PTPRQ in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.61	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	PTPRQ
Name	protein tyrosine phosphatase, receptor type, Q
Aliases	DFNB84; deafness, autosomal recessive 84; DFNB84A; PTPGMC1; R-PTP-Q; phosphotidylinositol phosphatase PTPRQ; ......
Chromosomal Location	12q21.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of PTPRQ in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0	1
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0	1
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0	1
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.168	0.797
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.111	0.913
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.254	0.831
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.13	0.855
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.005	0.441
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.558	0.743
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.058	0.888
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.058	0.926
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.255	0.48

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of PTPRQ in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	0	0	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	0	0	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	23.8	29.4	-5.6	0.727
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	37.5	16.7	20.8	0.58
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	36.4	-21	0.357
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	7.9	22.2	-14.3	0.147
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	15.4	-6.3	0.618
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	28.6	-22.4	0.157
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	9.1	7.7	1.4	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	20	8.3	11.7	0.515

Summary
Symbol	PTPRQ
Name	protein tyrosine phosphatase, receptor type, Q
Aliases	DFNB84; deafness, autosomal recessive 84; DFNB84A; PTPGMC1; R-PTP-Q; phosphotidylinositol phosphatase PTPRQ; ......
Chromosomal Location	12q21.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PTPRQ. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	PTPRQ
Name	protein tyrosine phosphatase, receptor type, Q
Aliases	DFNB84; deafness, autosomal recessive 84; DFNB84A; PTPGMC1; R-PTP-Q; phosphotidylinositol phosphatase PTPRQ; ......
Chromosomal Location	12q21.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PTPRQ. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PTPRQ. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	PTPRQ
Name	protein tyrosine phosphatase, receptor type, Q
Aliases	DFNB84; deafness, autosomal recessive 84; DFNB84A; PTPGMC1; R-PTP-Q; phosphotidylinositol phosphatase PTPRQ; ......
Chromosomal Location	12q21.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PTPRQ. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	PTPRQ
Name	protein tyrosine phosphatase, receptor type, Q
Aliases	DFNB84; deafness, autosomal recessive 84; DFNB84A; PTPGMC1; R-PTP-Q; phosphotidylinositol phosphatase PTPRQ; ......
Chromosomal Location	12q21.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of PTPRQ expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	PTPRQ
Name	protein tyrosine phosphatase, receptor type, Q
Aliases	DFNB84; deafness, autosomal recessive 84; DFNB84A; PTPGMC1; R-PTP-Q; phosphotidylinositol phosphatase PTPRQ; ......
Chromosomal Location	12q21.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between PTPRQ and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	PTPRQ
Name	protein tyrosine phosphatase, receptor type, Q
Aliases	DFNB84; deafness, autosomal recessive 84; DFNB84A; PTPGMC1; R-PTP-Q; phosphotidylinositol phosphatase PTPRQ; ......
Chromosomal Location	12q21.31
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting PTPRQ collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse PTPRQ